AbbVie
ABBV
$158.14
Share price
-5.47%
Change (1 day)
-4.10%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Operating Margin for AbbVie (ABBV)
Operating Margin as of April 2024 (TTM): 18.65%
According to AbbVie's latest financial reports and stock price the company's current Operating Margin is 18.65%. At the end of 2022 the company had an Operating Margin of 23.21%.
Operating Margin history for AbbVie from 2011 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2022 | 23.21% | 0.44% |
| 2021 | 23.11% | 211.56% |
| 2020 | 7.42% | -70.71% |
| 2019 | 25.33% | 59.63% |
| 2018 | 15.87% | -42.06% |
| 2017 | 27.39% | -10.95% |
| 2016 | 30.75% | 5.79% |
| 2015 | 29.07% | 144.93% |
| 2014 | 11.87% | -58.17% |
| 2013 | 28.38% | -8.9% |
| 2012 | 31.15% | 48.11% |
| 2011 | 21.03% | -31.99% |
| 2010 | 30.92% | -26.13% |
| 2009 | 41.86% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 34.61% | 85.58% | 🇺🇸 USA |
 Eli Lilly LLY | 24.66% | 32.23% | 🇺🇸 USA |
 Amgen AMGN | 34.59% | 85.47% | 🇺🇸 USA |
 Biogen BIIB | 31.30% | 67.83% | 🇺🇸 USA |
 Gilead Sciences GILD | 26.84% | 43.91% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 19.24% | 3.16% | 🇺🇸 USA |
 AstraZeneca AZN | 5.63% | -69.81% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 22.54% | 20.86% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | 14.36% | -23.00% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.